ARTRYA Ltd (AYA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ARTRYA Ltd (AYA) has a cash flow conversion efficiency ratio of -0.122x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-10.88 Million ≈ $-7.70 Million USD) by net assets (AU$89.35 Million ≈ $63.22 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ARTRYA Ltd (AYA) market capitalisation for the company's overall valuation and market capitalisation.
ARTRYA Ltd - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how ARTRYA Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ARTRYA Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ARTRYA Ltd ranked by their cash flow conversion efficiency. See ARTRYA Ltd cash debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai Wondertek Software Co Ltd
SHG:603189
|
-0.014x |
|
ZKH Group Limited
NYSE:ZKH
|
0.079x |
|
Mandalay Resources Corp
TO:MND
|
0.109x |
|
Vinh Son Song Hinh Hydropower JSC
VN:VSH
|
0.063x |
|
Shandong Longda Meat Foodstuff Co Ltd
SHE:002726
|
-0.183x |
|
Eightco Holdings Inc.
NASDAQ:ORBS
|
-0.013x |
|
SVI Public Company Limited
BK:SVI
|
0.060x |
|
Zedcor Energy
V:ZDC
|
0.031x |
Annual Cash Flow Conversion Efficiency for ARTRYA Ltd (2019–2025)
The table below shows the annual cash flow conversion efficiency of ARTRYA Ltd from 2019 to 2025. View AYA stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$21.29 Million ≈ $15.06 Million |
AU$-14.27 Million ≈ $-10.10 Million |
-0.670x | +26.89% |
| 2024-06-30 | AU$16.80 Million ≈ $11.89 Million |
AU$-15.41 Million ≈ $-10.90 Million |
-0.917x | -160.90% |
| 2023-06-30 | AU$30.56 Million ≈ $21.62 Million |
AU$-10.74 Million ≈ $-7.60 Million |
-0.351x | -48.68% |
| 2022-06-30 | AU$40.64 Million ≈ $28.76 Million |
AU$-9.61 Million ≈ $-6.80 Million |
-0.236x | -711.62% |
| 2021-06-30 | AU$51.05 Million ≈ $36.12 Million |
AU$-1.49 Million ≈ $-1.05 Million |
-0.029x | +95.53% |
| 2020-06-30 | AU$2.49 Million ≈ $1.76 Million |
AU$-1.62 Million ≈ $-1.15 Million |
-0.651x | -478.82% |
| 2019-06-30 | AU$852.97K ≈ $603.53K |
AU$-95.94K ≈ $-67.89K |
-0.112x | -- |
About ARTRYA Ltd
Artrya Limited, a medical technology company, engages in the development and commercialization of artificial intelligence platform that detects, diagnoses, and address coronary artery disease in Australia. The company offers Salix, a suite ifcloud-based software that uses artificial intelligence to automate the detection of coronary artery disease from coronary computed tomography angiography sca… Read more